Anti-tumor activity mediated by protein and peptide transduction of HIV viral protein R (Vpr)

Cancer Biology and Therapy

Volumn 8, Issue 2, 2009, Pages 180-187

  Muthumani, Karuppiah ^a   Lambert, Vance M ^b   Shanmugam, Mayilvahanan ^c   Thieu, Khanh P ^d   Choo, Andrew Y ^d   Chung, J Christopher W ^a   Satishchandran, Abhishek ^a   Kim, J Joseph ^e   Weiner, David B ^a   Ugen, Kenneth E ^b,f  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c Simons Center for Quantitative Biology   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e VGX Pharmaceuticals Inc   (United States)

^f UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Apoptosis; Cytotoxicity; HIV 1; Melanoma; Peptide; Protein transduction domain; Tat; Tumor cells; Vpr

Indexed keywords

TRANSACTIVATOR PROTEIN; TRANSACTIVATOR PROTEIN VPR PROTEIN CONJUGATE; UNCLASSIFIED DRUG; VPR PROTEIN;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; GENE CONSTRUCT; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MELANOMA CELL; MOUSE; NONHUMAN; PROTEIN DOMAIN;

EID: 58749096711     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.8.2.7205     Document Type: Article

References (70)

1. Kim JJ. Using viral genomics to develop viral gene products as a novel class of drugs to treat human ailments. Biotechnology Letters 2001; 23:1015-20.
2. Haseltine WA. Molecular biology of the human immunodeficiency virus type 1. FASEB J 1991; 5:2349-60.
3. Levy DN, Refaeli Y, MacGregor RR, Weiner DB. Serum Vpr regulates productive infection and latency of human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1994; 91:10873-7.
4. Goh WC, Rogel ME, Kinsey CM, Michael SF, Fultz PN, Nowak MA, Hahn BH, Emerman M. HIV-1 Vpr increases viral expression by manipulation of the cell cycle: a mechanism for selection of Vpr in vivo. Nat Med 1998; 4:65-71.
5. Eckstein DA, Sherman MP, Penn ML, Chin PS, De Noronha CM, Greene WC, Goldsmith MA. HIV-1 Vpr enhances viral burden by facilitating infection of tissue macrophages but not nondividing CD4+ T cells. J Exp Med 2001; 194:1407-19.
6. Di Marzio P, Choe S, Ebright M, Knoblauch R, Landau NR. Mutational analysis of cell cycle arrest, nuclear localization and virion packaging of human immunodeficiency virus type 1 Vpr. J Virol 1995; 69:7909-16.
7. Andersen JL, Le Rouzic E, Planelles V. HIV-1 Vpr: mechanisms of G2 arrest and apoptosis. Exp Mol Pathol 2008; 85:2-10.
8. Stewart SA, Poon B, Jowett JB, Xie Y, Chen IS. Lentiviral delivery of HIV-1 Vpr protein induces apoptosis in transformed cells. Proc Natl Acad Sci USA 1999; 96:12039-43.
9. Shostak LD, Ludlow J, Fisk J, Pursell S, Rimel BJ, Nguyen D, Rosenblatt JD, Planelles V. Roles of p53 and caspases in the induction of cell cycle arrest and apoptosis by HIV-1 vpr. Exp Cell Res 1999; 251:156-65.
10. Muthumani K, Choo AY, Hwang DS, Chattergoon MA, Dayes NN, Zhang D, Lee MD, Duvvuri U, Weiner DB. Mechanism of HIV-1 viral protein R-induced apoptosis. Biochem Biophys Res Commun 2003; 304:583-92.
11. Muthumani K, Choo A, Hwang DS, Ugen KE, Weiner DB. HIV-1 Vpr enhancing sensitivity of tumors to apoptosis. Current Drug Delivery 2004; 1:335-44.
12. McCray AN, Ugen KE, Muthumani K, Kim JJ, Weiner DB, Heller R. Complete regression of established subcutaneous B16 murine melanoma tumors after delivery of an HIV-1 Vpr-expressing plasmid by in vivo electroporation. Mol Ther 2006; 14:647-55.
13. McCray AN, Ugen KE, Heller R. Enhancement of anti-melanoma activity of a plasmid expressing HIV-1 Vpr delivered through in vivo electroporation. Cancer Biol Ther 2007; 6:1269-75.
14. Mahalingam S, MacDonald B, Ugen KE, Ayyavoo V, Agadjanyan MG, Williams WV, Weiner DB. In vitro and in vivo tumor growth suppression by HIV-1 Vpr. DNA Cell Biol 1997; 16:137-43.
15. Muthumani K, Zhang D, Hwang DS, Kudchodkar S, Dayes NS, Desai BM, Malik AS, Yang JS, Chattergoon MA, Maguire HC Jr, Weiner DB. Adenovirus encoding HIV-1 Vpr activates caspase 9 and induces apoptotic cell death in both p53 positive and negative human tumor cell lines. Oncogene 2002; 21:4613-25.
16. Stewart SA, Poon B, Jowett JB, Chen IS. Human immunodeficiency virus type 1 Vpr induces apoptosis following cell cycle arrest. J Virol 1997; 71:5579-92.
17. Ayyavoo V, Mahboubi A, Mahalingam S, Ramalingam R, Kudchodkar S, Williams WV, Green DR, Weiner DB. HIV-1 Vpr suppresses immune activation and apoptosis through regulation of nuclear factor kappaB. Nat Med 1997; 3:1117-23.
18. Schwarze SR, Dowdy SF. In vivo protein transduction: intracellular delivery of biologically active proteins, compounds and DNA. Trends Pharmacol Sci 2000; 21:45-8.
19. Yao XJ, Subbramanian RA, Rougeau N, Boisvert F, Bergeron D, Cohen EA. Mutagenic analysis of human immunodeficiency virus type 1 Vpr: role of a predicted N-terminal alpha-helical structure in Vpr nuclear localization and virion incorporation. J Virol 1995; 69:7032-44.
20. Yao S, Torres AM, Azad AA, Macreadie IG, Norton RS. Solution structure of peptides from HIV-1 Vpr protein that cause membrane permeabilization and growth arrest. J Pept Sci 1998; 4:426-35.
21. Ramanathan MP, Curley E, 3rd, Su M, Chambers JA, Weiner DB. Carboxyl terminus of hVIP/mov34 is critical for HIV-1-Vpr interaction and glucocorticoid-mediated signaling. J Biol Chem 2002; 277:47854-60.
22. Mahalingam S, Ayyavoo V, Patel M, Kieber-Emmons T, Kao GD, Muschel RJ, Weiner DB. HIV-1 Vpr interacts with a human 34-kDa mov34 homologue, a cellular factor linked to the G2/M phase transition of the mammalian cell cycle. Proc Natl Acad Sci USA 1998; 95:3419-24.
23. Prochiantz A. Messenger proteins: homeoproteins, TAT and others. Curr Opin Cell Biol 2000; 12:400-6.
24. Elliott G, O'Hare P. Intercellular trafficking and protein delivery by a herpesvirus structural protein. Cell 1997; 88:223-33.
25. Derossi D, Joliot AH, Chassaing G, Prochiantz A. The third helix of the Antennapedia homeodomain translocates through biological membranes. J Biol Chem 1994; 269:10444-50.
26. Torchilin VP, Levchenko TS, Rammohan R, Volodina N, Papahadjopoulos- Sternberg B, D'Souza GG. Cell transfection in vitro and in vivo with nontoxic TAT peptide-liposome-DNA complexes. Proc Natl Acad Sci USA 2003; 100:1972-7.
27. Kip1 induces cell migration. Nat Med 1998; 4:1449-52.
28. Mann DA, Frankel AD. Endocytosis and targeting of exogenous HIV-1 Tat protein. EMBO J 1991; 10:1733-9.
29. Green M, Loewenstein PM. Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein. Cell 1988; 55:1179-88.
30. Frankel AD, Pabo CO. Cellular uptake of the tat protein from human immunodeficiency virus. Cell 1988; 55:1189-93.
31. McGregor DP. Discovering and improving novel peptide therapeutics. Curr Opin Pharmacol 2008.
32. Lathman PW. Therapeutic peptides revisited. Nat Biotech 1999; 17:755-7.
33. Chen T. Re-evaluation of HeLa, HeLaS3 and HEp-2 karyotypes. Cytogenet Cell Genetics 1988; 48:19-24.
34. El-Badry OM, Romanus JA, Helman LJ, Cooper MJ, Rechler MM, Israel MA. Autonomous growth of a human neuroblastoma cell line is mediated by insulin-like growth factor II. J Clin Invest 1989; 84:829-39.
35. McAllister RM, Isaacs H, Rongey R, Peer M, Au W, Soukup SW, Gardner MB. Establishment of a human medulloblastoma cell line. Int J Cancer 1977; 20:206-12.
36. Engel LW, Young NA. Human breast carcinoma cells in continuous culture: a review. Cancer Res 1978; 38:4327-39.
37. Tsuchiya S, Yamabe M, Yamaguchi Y, Kobayashi Y, Konno T, Tada K. Establishment and characterization of a human acute monocytic leukemia cell line (THP-1). Int J Cancer 1980; 26:171-6.
38. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, Murphy GP. LNCaP model of human prostatic carcinoma. Cancer Res 1983; 43:1809-18.
39. Briles EB, Kornfeld S. Isolation and metastatic properties of detachment variants of B16 melanoma cells. J Natl Cancer Inst 1978; 60:1217-22.
40. Ngamwongsatit P, Banada PP, Panbangred W, Bhunia AK. WST-1-based cell cytotoxicity assay as a substitute for MTT-based assay for rapid detection of toxigenic Bacillus species using CHO cell line. J Microbiol Methods 2008; 73:211-5.
41. Loveland BE, Johns TG, Mackay IR, Vaillant F, Wang ZX, Hertzog PJ. Validation of the MTT dye assay for enumeration of cells in proliferative and antiproliferative assays. Biochem Int 1992; 27:501-10.
42. Kluza J, Lansiaux A, Wattez N, Hildebrand MP, Leonce S, Pierre A, Hickman JA, Bailly C. Induction of apoptosis in HL-60 leukemia and B16 melanoma cells by the acronycine derivative S23906-1. Biochem Pharmacol 2002; 63:1443-52.
43. Muthumani K, Choo AY, Zong WX, Madesh M, Hwang DS, Premkumar A, Thieu KP, Emmanuel J, Kumar S, Thompson CB, Weiner DB. The HIV-1 Vpr and glucocorticoid receptor complex is a gain-of-function interaction that prevents the nuclear localization of PARP-1. Nat Cell Biol 2006; 8:170-9.
44. Muthumani K, Choo AY, Hwang DS, Premkumar A, Dayes NS, Harris C, Green DR, Wadsworth SA, Siekierka JJ, Weiner DB. HIV-1 Nef-induced FasL induction and bystander killing requires p38 MAPK activation. Blood 2005; 106:2059-68.
45. Sherman MP, Schubert U, Williams SA, de Noronha CM, Kreisberg JF, Henklein P, Greene WC. HIV-1 Vpr displays natural protein-transducing properties: implications for viral pathogenesis. Virology 2002; 302:95-105.
46. Muthumani K, Hwang DS, Desai BM, Zhang D, Dayes N, Green DR, Weiner DB. HIV-1 Vpr induces apoptosis through caspase 9 in T cells and peripheral blood mononuclear cells. J Biol Chem 2002; 277:37820-31.
47. Sekaly RP. The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? J Exp Med 2008; 205:7-12.
48. Wender PA, Mitchell DJ, Pattabiraman K, Pelkey ET, Steinman L, Rothbard JB. The design, synthesis and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters. Proc Natl Acad Sci USA 2000; 97:13003-8.
49. Taguchi T, Shimura M, Osawa Y, Suzuki Y, Mizoguchi I, Niino K, Takaku F, Ishizaka Y. Nuclear trafficking of macromolecules by an oligopeptide derived from Vpr of human immunodeficiency virus type-1. Biochem Biophys Res Commun 2004; 320:18-26.
50. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 1999; 285:1569-72.
51. Roumier T, Vieira HL, Castedo M, Ferri KF, Boya P, Andreau K, Druillennec S, Joza N, Penninger JM, Roques B, Kroemer G. The C-terminal moiety of HIV-1 Vpr induces cell death via a caspase-independent mitochondrial pathway. Cell Death Differ 2002; 9:1212-9.
52. Andersen JL, Zimmerman ES, DeHart JL, Murala S, Ardon O, Blackett J, Chen J, Planelles V. ATR and GADD45alpha mediate HIV-1 Vpr-induced apoptosis. Cell Death Differ 2005; 12:326-34.
53. Toy EP, Rodriguez-Rodriguez L, McCance D, Ludlow J, Planelles V. Induction of cell cycle arrest in cervical cancer cells by the human immunodeficiency virus type 1 viral protein R. Obstet Gynecol 2000; 95:141-6.
54. Pang S, Kang MK, Kung S, Yu D, Lee A, Poon B, Chen IS, Lindemann B, Park NH. Anticancer effect of a lentiviral vector capable of expressing HIV-1 Vpr. Clin Cancer Res 2001; 7:3567-73.
55. Overwijk WW, Restifo NP. B16 as a mouse model for human melanoma. Current Protocol Immunol 2001; 20.
56. Klein G, Klein E. Immune surveillance against virus-induced tumors and nonrejectability of spontaneous tumors: contrasting consequences of host versus tumor evolution. Proc Natl Acad Sci USA 1977; 74:2121-5.
57. Hewitt HB, Blake ER, Walder AS. A critique of the evidence for active host defence against cancer, based on personal studies of 27 murine tumours of spontaneous origin. Br J Cancer 1976; 33:241-59.
58. Pan ZK, Weiskirch LM, Paterson Y. Regression of established B16F10 melanoma with a recombinant Listeria monocytogenes vaccine. Cancer Res 1999; 59:5264-9.
59. Fawell S, Seery J, Daikh Y, Moore C, Chen LL, Pepinsky B, Barsoum J. Tat-mediated delivery of heterologous proteins into cells. Proc Natl Acad Sci USA 1994; 91:664-8.
60. Matsuda M, Matsuda N, Watanabe A, Fujisawa R, Yamamoto K, Matusda M. Cell cycle arreset induction by an adenoviral vector expressing HIV-1 Vpr in bovine and feline cells. Biochem Biophys Res Commun 2003; 311:748-53.
61. + lymphocytes. Apoptosis 1997; 2:69-76.
62. Sherr CJ, McCormick F. The RB and p53 pathways in cancer. Cancer Cell 2002; 2:103-12.
63. Selivanova G, Iotsova V, Okan I, Fritsche M, Strom M, Groner B, Grafstrom RC, Wiman KG. Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Nat Med 1997; 3:632-8.
64. Snyder EL, Meade BR, Saenz CC, Dowdy SF. Treatment of terminal peritoneal carcinomatosis by a transducible p53-activating peptide. PLoS Biology 2004; 2:36.
65. Harbour JW, Worley L, Ma D, Cohen M. Transducible peptide therapy for uveal melanoma and retinoblastoma. Arch Ophthalmol 2002; 120:1341-6.
66. Rocco JW, Sidransky D. p16(MTS-1/CDKN2/INK4a) in cancer progression. Exp Cell Res 2001; 264:42-55.
67. INK4a peptides inhibit hypophosphorylation of the retinoblastoma protein and cell cycle progression prior to activation of Cdk2 complexes in late G1. Cancer Res 1999; 59:2577-80.
68. Yan H, Thomas J, Liu T, Raj D, London N, Tandeski T, Leachman SA, Lee RM, Grossman D. Induction of melanoma cell apoptosis and inhibition of tumor growth using a cell-permeable Survivin antagonist. Oncogene 2006; 25:6968-74.
69. Vives E, Brodin P, Lebleu B. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem 1997; 272:16010-7.
70. Siddiqui K, Del Valle L, Morellet N, Cui J, Ghafouri M, Mukerjee R, Urbanska K, Fan S, Pattillo CB, Deshmane SL, Kiani MF, Ansari R, Khalili K, Roques BP, Reiss K, Bouaziz S, Amini S, Srinivasan A, Sawaya BE. Molecular mimicry in inducing DNA damage between HIV-1 Vpr and the anticancer agent, cisplatin. Oncogene 2008; 27:32-43.